combined immunization-Sinovac Biotech Co., Ltd-COVID-19-influenza-pneumococcal pneumonia

This combined immunization regimen refers to the co-administration of three separate vaccines developed by Sinovac Biotech Co., Ltd: CoronaVac (an inactivated SARS-CoV-2 vaccine), an inactivated quadrivalent influenza vaccine (IIV4), and a 23-valent pneumococcal polysaccharide vaccine (PPV23). The regimen was evaluated in a Phase 4 clinical trial to assess the safety and immunogenicity of administering a third booster dose of CoronaVac simultaneously with the influenza and pneumococcal vaccines in healthy adults and the elderly. CoronaVac contains 600 SU of inactivated SARS-CoV-2 antigen, the IIV4 contains 15 μg of hemagglutinin per strain, and the PPV23 contains 25 μg of each of 23 pneumococcal serotype polysaccharides. All three components are biologics administered via intramuscular injection to provide broad protection against COVID-19, seasonal influenza, and pneumococcal pneumonia.

Brand names

CoronaVac

Other names

CoronaVac + Sinovac quadrivalent influenza vaccine + Sinovac 23-valent pneumococcal polysaccharide vaccineCo-administration of CoronaVac Booster with Influenza and Pneumococcal Vaccines